ITM to Showcase COMPETE Trial Findings at SNMMI 2025
ITM Isotope Technologies Munich SE, recognized for its innovation in the field of radiopharmaceuticals, is gearing up to share pivotal insights from its Phase 3 COMPETE trial at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. Scheduled from June 21 to June 24, 2025, this event will take place in the vibrant city of New Orleans.
Understanding the COMPETE Trial
The COMPETE trial is central to ITM's mission, focusing on the evaluation of 177Lu-edotreotide, a synthetic targeted radiotherapeutic agent intended for patients battling Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial aims to highlight how 177Lu-edotreotide compares to traditional treatments such as everolimus, shedding light on the potential for improved outcomes in patient care.
Oral Presentation Details
One of the key features of ITM's presence at the SNMMI meeting will be an oral presentation led by Dr. Thomas A. Hope, a prominent figure in nuclear medicine. Dr. Hope will discuss the nuances of tumor uptake of 177Lu-edotreotide, illustrating how pre-therapeutic Ga-68 PET/CT imaging can effectively predict this uptake. This session is expected to be enlightening for both clinicians and researchers, providing a deeper understanding of how imaging can aid treatment planning.
Symposium Engagement
Additionally, ITM will host a symposium titled “Pursuing the Art and Science of RPT: COMPETE Results and the Evolution of Dosimetry.” This event aims to foster discussions surrounding the GEP-NET treatment landscape and delve into the findings of the COMPETE trial, particularly focusing on dosimetry standardization and its implications for current practice.
Participation in Entrepreneur’s Panel
ITM’s Chief Medical Officer, Dr. Celine Wilke, will also participate in an Entrepreneur’s Panel on June 21, focusing on accelerating clinical trials. This reflects ITM’s commitment to fostering collaboration and knowledge-sharing within the medical community.
Latest Innovations
Visitors to ITM’s booth at the conference will have the opportunity to learn about the company’s latest advancements in radiopharmaceutical therapy (RPT). ITM's focus on high-quality medical radioisotope production underscores its dedication to providing innovative treatment options for oncology.
About ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE stands at the forefront of radiopharmaceutical biotechnology, committed to innovating treatments that address the needs of cancer patients worldwide. With a pipeline of promising therapeutics, including several Phase 3 studies, ITM integrates high-quality radioisotopes with targeted molecules to strengthen precision oncology.
Frequently Asked Questions
What is the COMPETE trial?
The COMPETE trial investigates the efficacy of 177Lu-edotreotide in treating patients with GEP-NETs compared to everolimus.
Who will present at the SNMMI meeting?
Dr. Thomas A. Hope will present key insights from the COMPETE trial during an oral session.
What topics will be covered in the symposium?
The symposium will discuss treatment landscape insights, COMPETE trial results, and dosimetry evolution.
When will the symposium take place?
The symposium is scheduled for Sunday, June 22, from 6:30 pm to 7:30 pm CDT.
How can I learn more about ITM’s innovations?
Visit ITM’s booth at the SNMMI 2025 annual meeting for detailed information on their latest radiopharmaceutical therapies.
